# A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis

> **NCT03627468** · PHASE3 · COMPLETED · sponsor: **Botanix Pharmaceuticals** · enrollment: 300 (actual)

## Conditions studied

- Primary Axillary Hyperhidrosis

## Interventions

- **DRUG:** Sofpironium Bromide Gel, 5%
- **DRUG:** Sofpironium Bromide Gel, 15%

## Key facts

- **NCT ID:** NCT03627468
- **Lead sponsor:** Botanix Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-05
- **Primary completion:** 2020-01-27
- **Final completion:** 2020-01-27
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2023-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03627468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03627468, "A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03627468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*